DailyIQ
|
Sector:Consumer DefensiveAll sectors
Last updated 2 minutes ago

CLX·The Clorox Company

$.
-. (-.%)
Pre-Market
High
$96.00
Open
$95.00
Market Cap
11.71B
52W High
$132.03
Low
$95.00
P. Close
$96.01
P/E
15.49
52W Low
$84.70
Fwd P/E
15.28
Mean Target
$105.29
Technical Score (1D)
32
SELL
News Sentiment
53
MIXED
The Clorox Company has officially begun its search for a new Chief Executive Officer, following the recent departure of CEO Linda Rendle due to health reasons. Rendle will continue in her roles during the transition and will provide advisory support to ensure a smooth handover. This leadership transition is a significant development for the consumer staples giant, and investors will be closely monitoring the succession plan and its potential impact on the company's strategic direction. The board has formed an independent committee to lead the CEO search process. The company operates across multiple consumer product segments, boasting a portfolio of well-known brands beyond its namesake, with over 80% of sales generated domestically. This foundational understanding of Clorox's market presence and brand diversification is important context as the company navigates this leadership change. Investors are also considering Clorox's financial health and valuation against sector trends, with comparative analyses being made against peers like Kimberly-Clark and Procter & Gamble, focusing on metrics such as net margins and debt levels. The market will be watching for updates on the CEO search and any strategic shifts that may emerge under new leadership.
Earnings Summary
The Clorox Company is a prominent global manufacturer of consumer staples, specializing in household and healthcare essentials across its Health and Wellness, Household, Lifestyle, and International segments. The company leverages well-known brands such as Clorox, Glad, and Brita to provide cleaning, home care, and personal wellness solutions. Clorox's distribution strategy ensures broad accessibility through mass merchants, grocery stores, and online channels, reinforcing its strong market position built on meeting everyday consumer needs since its founding in 1913. In its recent quarterly performance, Clorox has shown variability. For Q3 2025, the company reported actual EPS of $0.85, surpassing the estimate of $0.78, with revenue at $1.43 billion. This followed a strong Q2 2025 where actual EPS was $2.87, significantly exceeding the estimate of $2.21, and revenue reached $1.99 billion. However, Q1 2025 saw actual EPS of $1.45, missing the estimate of $1.56, with revenue at $1.67 billion. The trend indicates a notable acceleration in EPS and revenue growth in Q2 2025, followed by a moderation in Q3 2025, though EPS still beat estimates. Historically, Clorox's earnings performance has been inconsistent, with a pattern of both beats and misses against analyst estimates. For instance, the company beat EPS estimates in Q4 2024, Q2 2025, and Q3 2025, but missed in Q1 2025. Revenue figures have also shown fluctuations, with Q2 2026 revenue slightly exceeding estimates while Q3 2026 revenue also beat estimates. This suggests a dynamic operating environment where the company's ability to meet expectations can vary quarter to quarter. Recent news highlights Clorox executives presenting at the dbAccess Global Consumer Conference, offering investors direct insight into the company's strategy and performance. This comes at a time when Wall Street sentiment is neutral, and some funds have reduced holdings, potentially signaling a cautious outlook influenced by broader market headwinds. The historical success of acquisitions, like Hidden Valley Ranch, is also noted as a testament to Clorox's brand expansion capabilities. Looking forward, investors will be closely monitoring Clorox's presentations and upcoming financial reports for directional clarity and insights into its strategic direction. Key watch points will include how management addresses current market challenges, such as inflation and geopolitical factors, and its ability to leverage its established brands for future growth. The company's performance in navigating these dynamics and its execution on strategic initiatives will be crucial for investor confidence in the coming quarters.

EPS

EstBeatMiss
$0.46$1.14$1.82$2.50$3.18Q1'25Q2'25Q3'25Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$1.66 - -
Q3'26$1.55$1.64+6.1%
Q2'26$1.57$1.39-11.5%
Q3'25$0.78$0.85+9.2%
Q2'25$2.21$2.87+29.7%
Q1'25$1.56$1.45-6.9%

Revenue

EstBeatMiss
$1.3B$1.5B$1.7B$1.9B$2.1BQ1'25Q2'25Q3'25Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$1.9B - -
Q3'26$1.7B$1.7B+0.1%
Q2'26$1.7B$1.7B+0.0%
Q3'25 - $1.4B -
Q2'25 - $2.0B -
Q1'25 - $1.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

CLX Stock Snapshot

CLX is currently trading at $95.57, giving The Clorox Company a market cap of 11.71B and a P/E ratio of 15.5. Today's range spans $95.00–$96.00, with shares opening at $95.00 and moving down $0.44 (0.5%) from the prior close. DailyIQ's technical score sits at 32/100 (SELL) with a news sentiment reading of 53/100.

Over the past year CLX has traded between $84.70 and $132.03 - the current price is +12.8% off the 52-week low and -27.6% from the high. 27 analysts cover the stock with a Hold consensus and a mean 12-month target of $105.29 (range $83.00–$163.00), implying upside of +10.2%.

The Clorox Company (CLX) is at $95.57 (in the lower half of its 52-week range in $84.70–$132.03), carrying a SELL signal (32/100) and neutral sentiment (53/100). The current P/E ratio stands at 15.5. The 11.71B market cap in Consumer Defensive means this name is well-covered by analysts who can accelerate the downside through rating cuts and target reductions - a feedback loop that smaller stocks with less coverage don't face to the same degree.

Analyst coverage for CLX becomes a double-edged factor in a SELL phase: at 11.71B in Consumer Defensive market cap, active coverage is high enough that downgrade risk is real and impactful. The 32/100 technical reading and neutral sentiment (53/100) at $95.57 (in the lower half of its 52-week range) place the stock in the zone where one or two high-profile estimate cuts can convert a grinding decline into a sharper re-rating — the $84.70–$132.03 range establishes where that repricing lands.